Pulmonary Rehabilitation in Patients Before Lung Transplantation (LTx)

N/ACompletedNCT00962078

Schön Klinik Berchtesgadener Land71 enrolled

Overview

The purpose of this study is to study the effects of a complex pulmonary rehabilitation program on mobility measured by 6 minute walking distance (6MWD) and physical activity, measured via Dynaport and Actibelt Aktivitätsmonitor, dyspnoea (VAS), quality of life (HRQL (SF36, EuroQul)), anxiety and depression (HADS)and PaCO2-behavior under physical activity.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

COPD Pre-Lung-Transplantation Hypercapnia Respiratory Insufficiency

Interventions

continuous endurance trainingOTHER

at 60 percent of peak Watt

interval trainingOTHER

at 100 percent of peak Watt

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * pre-LTx (listed for lung-transplantation or currently undergoing evaluation) * COPD Stadium IV GOLD * α-1-Antitrypsin-deficiency-Emphysema * respiratory Insufficiency * oxygen therapy (LTOT) Exclusion Criteria: * serious Exacerbation (Symptoms longer than three days, change of therapy, e.i. antibiotics, steroids) during the last four weeks before rehabilitation * clinical signs of manifest heart insufficiency * acute coronar syndrome * left heart insufficiency(EF \< 40%) * missing Compliance

Locations (1)

Klinikum Berchtesgadener Land

Schönau am Königssee, Germany

Outcomes

Primary Outcomes

Effects of a Multimodal Pulmonary Rehabilitation Program on 6 Minute Walking Distance (6MWD)

Time frame: value at day 21 minus value at day 1

Secondary Outcomes

Dyspnoea During Exercise Measured on the Borg Scale

The Borg scale is a numeric scale that ranges from 0 to 10 points to rate dyspnea. The scale is like follows: 0 Nothing at all 1. Very slight 2. Slight 3. Moderate 4. Somewhat severe 5. Severe 7 Very severe 8 9 Very, very severe (almost maximal) 10 Maximal

Time frame: mean values from day 1 to day 21

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.